NY-GARIA
5.10.2021 16:55:09 CEST | Business Wire | Press release
Viridi Parente, Inc., a developer of innovative battery technology that can be safely installed and operated in nearly any environment or location, is partnering with Garia Utility , the Denmark-based leader in low-speed utility vehicles , to develop last-mile , low-speed electric utility vehicles for the U.S. market. These vehicles will be manufactured in Buffalo, New York, and branded under the Green Machine Equipment name.
An image of the Green Machine electric, low-speed utility vehicle may be downloaded here - https://rb.gy/uywc9e .
"If we are going to have any impact on decarbonization, we need to rethink our supply chain strategies and equipment options, especially for last-mile delivery," said Jon M. Williams, CEO of Viridi Parente. "Green Machine couldn't ask for a better partner to introduce clean utility vehicles into the U.S. than Garia. Its proven technology is already deployed throughout Europe, and the compact design is ideally suited for use in dense, urban areas in the U.S."
Garia chose to partner with Green Machine because of its proprietary, durable, and safe battery technology that is being used by leading construction brands such as Bobcat and Case . Green Machine was the first manufacturer to introduce all-electric heavy construction and industrial equipment into the market and has perfected the technology with more than 250,000 hours of robust field testing.
Garia Utility has over 900 last-mile vehicles deployed on delivery routes in Sweden through a contract with PostNord (the Swedish Postal Service). The combination of Green Machine's propriety technology and Garia's know-how in the last-mile vehicle space creates a superb clean vehicle that replaces standard diesel or gasoline-powered utility vehicles . For U.S. markets, Green Machine battery technology will increase the range and adaptability of the vehicle.
"After evaluating many potential partners, Viridi Parente was the obvious choice," said Jakob Holstein, CEO of Garia. "Not only did they have the best technology for our needs, but their technology had the most field experience. We were also aligned well on leadership and values."
Green Machine's electric utility vehicles are unlike anything currently available in the U.S. The compact design allows users to access narrow spaces such as constricted roadways, tight alleys, or compressed park or campus pathways. In addition to the traditional model, Green Machine has installed its technology into a right-hand-drive chassis from Garia that squarely fits any delivery needs.
Still dominated by fossil-fuel-powered trucks and vehicles, the supply chain remains a significant source of greenhouse gasses. In New York, transportation accounts for about 36% of the state's carbon emissions. While the nation's reliance on an efficient, reliable supply chain increases, so does the desire to transition long-haul and last-mile delivery to zero-emission vehicle options. McKinsey forecasts that the number of electric utility vehicles will grow from just 5,000 in 2018 to more than 8 million by 2030.
About Viridi Parente
Viridi Parente (Viridi) is a disruptive energy company in Buffalo, New York, that is changing the way we use energy, improving systems, communities, and lives. Viridi deploys safe battery technology into applications that have been historically dominated by fossil fuel energy sources. Its innovative architecture is constructed from materials used for aerospace and military applications and is the only design in the market that can be safely installed and operated in nearly any environment or location. Through its subsidiary, Green Machine Equipment, Viridi is bringing quiet, fully renewable mobile energy solutions to products in construction equipment, waste disposal, last-mile delivery, and other portable industrial markets. Through its subsidiary, Volta Energy Products, Viridi brings stationary, point-of-use storage technology that is safe, locatable, and reliable to industrial, medical, commercial, municipal, and residential building applications. Learn more at: www.viridiparente.com .
About Garia A/S
Garia is a manufacturer of utility vehicles, premium golf, and leisure cars. Founded in 2005 by Anders Lynge, Garia is privately held by Lars Larsen Group and headquartered in Denmark with a subsidiary in the U.S.
In 2015, with ten years of experience in the luxury electric vehicle market, Garia embarked on an entirely new journey: the Garia Utility. A compact electric utility vehicle that combines reliability, ergonomics, and zero emissions with comfort, functionality, and thoughtful design. Made of high-quality European components, the Garia Utility is one of a kind.
Learn more about the Garia Utility at gariautility.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005881/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom